Role of histone deacetylases and their inhibitors in neurological diseases

被引:8
|
作者
Zhang, Li-Ying [1 ]
Zhang, Sen-Yu [1 ]
Wen, Ri [1 ]
Zhang, Tie-Ning [1 ]
Yang, Ni [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Pediat, PICU, Shenyang 110004, Peoples R China
关键词
Histone deacetylase; Neurological disease; Huntington's disease; Alzheimer's disease; Parkinson's disease; Histone deacetylase inhibitors; SUBEROYLANILIDE HYDROXAMIC ACID; DORSOLATERAL PREFRONTAL CORTEX; NF-KAPPA-B; MOUSE MODEL; VALPROIC ACID; SODIUM-BUTYRATE; GENE-EXPRESSION; CLASS-II; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE;
D O I
10.1016/j.phrs.2024.107410
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Histone deacetylases (HDACs) are zinc-dependent deacetylases that remove acetyl groups from lysine residues of histones or form protein complexes with other proteins for transcriptional repression, changing chromatin structure tightness, and inhibiting gene expression. Recent in vivo and in vitro studies have amply demonstrated the critical role of HDACs in the cell biology of the nervous system during both physiological and pathological processes and have provided new insights into the conduct of research on neurological disease targets. In addition, in vitro and in vivo studies on HDAC inhibitors show promise for the treatment of various diseases. This review summarizes the regulatory mechanisms of HDAC and the important role of its downstream targets in nervous system diseases, and summarizes the therapeutic mechanisms and efficacy of HDAC inhibitors in various nervous system diseases. Additionally, the current pharmacological situation, problems, and developmental prospects of HDAC inhibitors are described. A better understanding of the pathogenic mechanisms of HDACs in the nervous system may reveal new targets for therapeutic interventions in diseases and help to relieve healthcare pressure through preventive measures.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases
    Qiu, Xiaoyan
    Xiao, Xiong
    Li, Nan
    Li, Yuemin
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2017, 72 : 60 - 72
  • [22] Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases
    Dekker, Frank J.
    van den Bosch, Thea
    Martin, Nathaniel I.
    DRUG DISCOVERY TODAY, 2014, 19 (05) : 654 - 660
  • [23] Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
    Hassell, Kelly N.
    DISEASES, 2019, 7 (04)
  • [24] The application of histone deacetylases inhibitors in glioblastoma
    Chen, Rui
    Zhang, Mengxian
    Zhou, Yangmei
    Guo, Wenjing
    Yi, Ming
    Zhang, Ziyan
    Ding, Yanpeng
    Wang, Yali
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [25] Dysregulation of histone deacetylases in ocular diseases
    Jae Hyun Jun
    Jun-Sik Kim
    Leon F. Palomera
    Dong-Gyu Jo
    Archives of Pharmacal Research, 2024, 47 (1) : 20 - 39
  • [26] Histone deacetylases and transcriptional therapy with their inhibitors
    Pandolfi, PP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (Suppl 1) : S17 - S19
  • [27] The application of histone deacetylases inhibitors in glioblastoma
    Rui Chen
    Mengxian Zhang
    Yangmei Zhou
    Wenjing Guo
    Ming Yi
    Ziyan Zhang
    Yanpeng Ding
    Yali Wang
    Journal of Experimental & Clinical Cancer Research, 39
  • [28] Targeting histone deacetylases for heart diseases
    Jin, Gang
    Wang, Kaiyue
    Zhao, Yaohui
    Yuan, Shuo
    He, Zhangxu
    Zhang, Jingyu
    BIOORGANIC CHEMISTRY, 2023, 138
  • [29] HISTONE DEACETYLASES: PROMOTERS AND INHIBITORS OF NEURODEGENERATION
    D'Mello, S. R.
    JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 12 - 12
  • [30] Histone deacetylases and transcriptional therapy with their inhibitors
    Pier Pandolfi
    Cancer Chemotherapy and Pharmacology, 2001, 48 : S17 - S19